1. Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephronsparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2009; 181:35-41.

2. Furhman SA, Lasky LC,Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.

3. Krajowy Rejestr Nowotworów. onkologia.org.pl /nowotworyzłośliwe- nerki-c67/

4. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumores. J Urol 2007;178: 41-46.

5. Pykało R, Wasiutyński A. Nowotwory nabłonkowe nerki – Patologia. W: Borkowski A, Czaplicki M, red. Nowotwory i torbiele nerek. PZWL. Warszawa 2002.

6. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol 1963; 89: 37.

7. Mevorach RA, Segaj AJ, Tersegno ME, Frank IN. Renal cell carcinoma: Incidental diagnosis and natural history. Review of 235 cases. Urology 1992; 39: 519-522.

8. Richie JP, Garnick MC. Primery renal and uretral cancer, In: Rieseback RE, Garnick MC, eds. Cancer and the Kidney. Philadelphia, Lea & Febiger 1982: 683-685.

9. Lighfoot N, Conlon M, Kreiger N, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol 2000; 37: 521-527.

10. Graser A, Becker CR, Staehler M, et al. Single-phase dualenergy CT allows for characterization of renal masses as benign or malignant. Invest Radiol 2010; 45: 399-405.

11. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology 2008; 249:16-31.

12. ljumberg B, Larsson P, Stenling R, Roos G. Flow cytometric deoxyribonucleonic acid analysis in stage I renal cell carcinoma. J Urol 1991; 146: 697.

13. Nurmi MJ. Prognostic factors in renal cell carcinoma: An evaluation of operative findings. Br J Urol 1984; 56: 270-275.

14. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101: 297-301.

15. Golimbu M, Joshi P, Sperber A. Renal cell carcinoma: Survivaland prognostic factors. Urology 1986; 27: 291-301.

16. Green LK, Ayala AG, Ro JY. Role of nuclear grading in stage I renal cell carcinoma. Urology 1989; 34: 310.

17. Ljunberg B, Joansson H, Stenling R. Prognostic factors in renal cell carcinoma. Int Urol Nephrol 1988; 20: 115-121.

18. Ljunberg B, Stenling R, Roos G.DNA content and prognosis in renal cell carcinoma: A comparision between primary tumors and metastases. Cancer 1986; 57:23-46.

19. Murphy GF, Partin AW, Maygarden SJ. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J Urol 1990; 143: 1103.

20. Selli C, Hinschaw WM, Woodward BH. Stratification of risk factors in renal cell carcinoma. Cancer 1983; 52: 899-903.

21. McNichols DW, Segura JW, DeWeerd JH. Renal cell carcinoma: Long term survival and late recurrence. J Urol 1981; 126: 17-23.

22. Kużnik Z, Dutkiewicz S. Postępowanie w przypadkach złośliwych guzów nerek w Klinice Urologii Instytutu Medycyny Klinicznej MSW. Probl Lek 1989; 28,2: 169-172.

23. Giuliani L, Giberti C, Martorona G, Rovida S. Radical extensive surgery for renal cell carcinoma: Long term results and prognostic factors. J Urol 1990; 143: 468-474.

24. Mickisch GH. No-touch nephrectomy: Still a necessity? Eur Urol Update Series 1998; 7: 115-117.

25. Provet J, Tessler A, Brown J, et al. Partial nephrectomy for renal cell carcinoma: indications, results and implications. J Urol 1991; 145: 472-476.

26. Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2009; 181: 35-41.

27. Gill IS,Kavoussi LR, Lane BR, et al. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J U rol 2007; 178: 41-46.

28. Blom JH, van Poppel H, Marechal JM, et al. EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Reserch and Treatment of Cancer randomized phase 3 trial 30881. Uur Urol 2009; 55: 28-34.

29. May M, Brookman-Amissah S, Pflanz S, et al. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol 2009; 82: 724-731.

30. www.nccn.org.

31. Aref I, Bociek G, Salhani D. Is postoperative radiotherapy for renal cell carcinoma justified? Radiother Oncol 1997; 43:155-157.

32. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alpha2b compared with interferon alpha2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655-1659.

33. Motzer RJ, Huston TE, Tomczak P, et al. Sunitynib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Meed 2007; 356:115-124.

34. Gitilitz BJ, Figlin RA. Cytokine-based therapy for metastatic renal cell carcinoma. Urol Clin North Am 2003; 30: 589-600.

35. Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clearcell renal-cell carcinoma.N Engl J Med 2007; 356: 125-134.

36. Sternberg CN, Davis ID, Mardiak J, et al. A randomized, double- blind phase III of pazopanib in treatment-aive and cytokine- pretreatedpatients with advanced renal cell carcinoma (RCC). J Clin Oncol 2010;28:1061-1068.

37. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phasse III trial. Lancet 2008; 372: 449-456.

38. Gohji K, Kamidono S, Yamanaka N. Renal carcinoma in a solitary kidney. Br J Urol 1990; 66: 248.

39. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing surgery. J Urol 1996; 155:1868-1873.

40. Novick AC. Nephron sparing surgery for renal cell carcinoma. Br J Urol 1998; 82:321.